Mithramycin-loaded mPEG-PLGA nanoparticles exert potent antitumor efficacy against pancreatic carcinoma.

about

Mithramycin-loaded mPEG-PLGA nanoparticles exert potent antitumor efficacy against pancreatic carcinoma.

Item

http://www.wikidata.org/entity/Q42284455

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Mithramycin-loaded mPEG-PLGA n ...... against pancreatic carcinoma.

@en

Mithramycin-loaded mPEG-PLGA n ...... against pancreatic carcinoma.

@nl

type

Item

label

Mithramycin-loaded mPEG-PLGA n ...... against pancreatic carcinoma.

@en

Mithramycin-loaded mPEG-PLGA n ...... against pancreatic carcinoma.

@nl

prefLabel

Mithramycin-loaded mPEG-PLGA n ...... against pancreatic carcinoma.

@en

Mithramycin-loaded mPEG-PLGA n ...... against pancreatic carcinoma.

@nl

P1476

Mithramycin-loaded mPEG-PLGA n ...... against pancreatic carcinoma.

@en

P2093

Chun-Yan Zhao

http://www.w3.org/2001/XMLSchema#string

Liang Li

http://www.w3.org/2001/XMLSchema#string

Rui-Qi Wang

http://www.w3.org/2001/XMLSchema#string

Xiu-Jun Liu

http://www.w3.org/2001/XMLSchema#string

Xu-Jie Liu

http://www.w3.org/2001/XMLSchema#string

Yi Li

http://www.w3.org/2001/XMLSchema#string

Yong-Su Zhen

http://www.w3.org/2001/XMLSchema#string

P2860

Inhibition of c-src transcription by mithramycin: structure-activity relationships of biosynthetically produced mithramycin analogues using the c-src promoter as target

Mithramycin A inhibits DNA methyltransferase and metastasis potential of lung cancer cells

CD47 update: a multifaceted actor in the tumour microenvironment of potential therapeutic interest

Mithramycin Depletes Specificity Protein 1 and Activates p53 to Mediate Senescence and Apoptosis of Malignant Pleural Mesothelioma Cells

Nanoparticle therapeutics: an emerging treatment modality for cancer

Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers.

Combined treatment of pancreatic cancer with mithramycin A and tolfenamic acid promotes Sp1 degradation and synergistic antitumor activity

Modulation of specificity protein 1 by mithramycin A as a novel therapeutic strategy for cervical cancer.

c-Myc oncoprotein: cell cycle-related events and new therapeutic challenges in cancer and cardiovascular diseases.

CD47-signal regulatory protein-α (SIRPα) interactions form a barrier for antibody-mediated tumor cell destruction.

P304

5255-5269

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/IJN.S139507

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-07-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28769562

http://www.w3.org/2001/XMLSchema#string

P932

5533565

http://www.w3.org/2001/XMLSchema#string